Raphaël Denis Books

Focusing on the evolving landscape of prostate disease, this book synthesizes insights from an International Symposium on its epidemiology. It highlights the intense debates surrounding diagnosis and treatment methods, with contributions from both urologists and epidemiologists. As clinical and laboratory research accelerates, the text emphasizes the importance of understanding the broader community impact of prostate disease through epidemiological perspectives. This comprehensive examination aims to inform future practices in managing prostate health.

This volume is a report of the proceedings of an International Symposium on Bladder Cancer and a selection of Urological papers presented at the Antwerp Medical Days in Antwerp, Belgium, on the 19th and 20th September 1980. The meeting was sponsored by the Antwerp Medical Days Program Committee supported by the Royal Antwerp Circle of Medicine, the Urological Group of the European Organization for Research on the Treatment of Cancer, the Belgische Vereniging voor Urologie, the Societe Belge d'Urologie, the Province and City of Antwerp and the National Fund for Scientific Medical Research of Belgium. Contributors were briefed to avoid too much overlapping, in the hope of obtaining a coherent compilation of clinical data. We are grateful for their discipline which enables early publication. All the contributions in this volume, except ~he section on immunology which was selected by the editors for its related inter est, were presented at the International Symposium under the sections 'Understanding the Disease', 'Therapeutic Approaches', 'Chemotherapy', and 'Prospective Studies'.

This supplement issue presents advances in knowledge of the main urological cancers from a multidisciplinary perspective. It opens with an in-depth overview of controversial issues in the diagnosis and treatment of prostate cancer, followed by a paper on animal models and preliminary experience with oral bropirimine in phase I-II trials. The next four presentations focus on superficial bladder cancer, and include an overview of recent literature and results from ongoing clinical trials. Further contributions demonstrate the importance of randomized clinical trials to the care of patients with bladder cancer and provide a complete review of the diagnosis and treatment of kidney cancer. The final papers deal with important, but often ignored, subjects: quality of life, statistical design of trials and health economics. Bringing together the expertise and experience of leading authorities, this issue is valuable reading for all those interested in optimizing the treatment of patients with urinary tract cancer.

The European School of Oncology was established to address the need for information, education, and training in cancer diagnosis and treatment. This initiative arose from two main challenges: the necessity for a multidisciplinary approach in oncology education, which universities struggle to implement due to their disciplinary focus, and the rapid technological advancements in cancer treatment that medical faculties find difficult to incorporate into their curricula. Through residential courses on organ pathologies and seminars covering new techniques (such as laser therapy, monoclonal antibodies, and imaging) as well as major therapeutic debates (like conservative versus mutilating surgery and the roles of chemotherapy and radiotherapy), the European School of Oncology aims to bridge the cultural and scientific divide between academia, industry, and everyday medical practice. A recent initiative includes the establishment of permanent study groups, or task forces, where a select group of leading experts convenes annually to define the current state of oncology and potentially reach a consensus on future developments in specific areas.